

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2024-25

Date: 15.11.2024

To

**BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001**

**National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051**

BSE Code-531146

NSE Code: MEDICAMEQ

Sub. : Copy of Publication for Un-Audited Financial Results for the quarter and half year ended on September 30, 2024

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 (“the Regulations”), please find enclosed newspaper cutting with regard to the publication of extract of Un-Audited Financial Results of the Company for the quarter and half year ended on September 30, 2024 approved by the Board of Directors at their Meeting held on 14.11.2024.

The copy of the results published in the Financial Express and Jansatta dated November 15, 2024 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited

**Parul Choudhary
Company Secretary
ACS-44157**

Encl: As above.



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
CIN: L74899DL 1993PLC056594 E-mail: cs@medicamen.com, Website: www.medicamen.com

Un-audited standalone and consolidated financial results for the quarter and half year ended on 30th September 2024

Rupees in Lacs(Except per Share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended		Half Year Ended		Year Ended	Quarter Ended			Half Year Ended	Year Ended		
		Un-Audited 30.09.2024	Un-Audited 30.06.2024	Un-Audited 30.09.2023	Un-Audited 30.09.2024	Un-Audited 30.09.2023	Audited 31.03.2024	Un-Audited 30.09.2024	Un-Audited 30.06.2024	Un-Audited 30.09.2023	Un-Audited 30.09.2024	Un-Audited 30.09.2023	Audited 31.03.2024
1	Total income from operations (net)	4313.35	4205.69	4322.08	8519.04	8410.34	17468.88	4503.30	4363.49	4409.12	8866.79	8641.35	18163.19
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	325.42	301.51	400.04	626.94	915.37	1688.79	195.64	155.63	246.45	351.27	714.78	1307.56
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	325.42	301.51	400.04	626.94	915.37	1688.79	195.64	155.63	246.45	351.27	714.78	1307.56
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	226.90	225.75	301.16	452.67	742.86	1329.80	90.39	79.87	147.67	177.00	542.37	949.40
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	226.90	225.75	301.16	452.67	742.86	1329.80	90.39	79.87	147.67	177.00	542.37	949.40
6	Equity Share Capital	1271.46	1271.46	1265.11	1271.46	1265.11	1271.46	1271.46	1265.11	1265.11	1271.46	1265.11	1271.46
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)												
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)												
	Basic:	1.78	1.78	2.38	3.56	5.87	10.50	0.71	0.63	1.17	1.39	4.29	7.50
	Diluted:	1.78	1.78	2.38	3.56	5.87	10.50	0.71	0.63	1.17	1.39	4.29	7.50

Note:

- The Un-audited financial results for the quarter ended 30.09.2024 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.11.2024
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The other expenses includes salary & other marketing expenses for domestic market and marketing expense for setting up network of Oncology Market
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -Earning per Share
- Limited Review has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited

Sd/-

Rahul Bishnoi

Chairman

Place : New Delhi

Date : 14.11.2024

...Continued from previous page

No. of Shares	No. of Applications	% to total	Total No. of Equity Shares	% to total	Proportionate Shares	Allocation per Applicant	Ratio of Allottees	Number of successful	% to total	Total No. of shares	% to total	Surplus
---------------	---------------------	------------	----------------------------	------------	----------------------	--------------------------	--------------------	----------------------	------------	---------------------	------------	---------

CORRIGENDUM TO RED

Investors shall note that the in



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
CIN: L74899DL 1993PLC056594 E-mail: cs@medicamen.com, Website: www.medicamen.com

Un-audited standalone and consolidated financial results for the quarter and half year ended on 30th September 2024

Rupees in Lacs(Except per Share data)

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended			Quarter Ended			Half Year Ended		
		Un-Audited 30.09.2024	Un-Audited 30.06.2024	Un-Audited 30.09.2023	Un-Audited 30.09.2024	Un-Audited 30.09.2023	Audited 31.03.2024	Un-Audited 30.09.2024	Un-Audited 30.06.2024	Un-Audited 30.09.2023	Un-Audited 30.09.2024	Un-Audited 30.09.2023	Audited 31.03.2024
1	Total income from operations (net)	4313.35	4205.69	4322.08	8519.04	8410.34	17468.88	4503.30	4363.49	4409.12	8866.79	8641.35	18163.19
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	325.42	301.51	400.04	626.94	915.37	1688.79	195.64	155.63	246.45	351.27	714.78	1307.56
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	325.42	301.51	400.04	626.94	915.37	1688.79	195.64	155.63	246.45	351.27	714.78	1307.56
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	226.90	225.75	301.16	452.67	742.86	1329.80	90.39	79.87	147.67	177.00	542.37	949.40
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	226.90	225.75	301.16	452.67	742.86	1329.80	90.39	79.87	147.67	177.00	542.37	949.40
6	Equity Share Capital	1271.46	1271.46	1265.11	1271.46	1265.11	1271.46	1271.46	1265.11	1265.11	1271.46	1265.11	1271.46
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)												
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)												
	Basic:	1.78	1.78	2.38	3.56	5.87	10.50	0.71	0.63	1.17	1.39	4.29	7.50
	Diluted:	1.78	1.78	2.38	3.56	5.87	10.50	0.71	0.63	1.17	1.39	4.29	7.50

- Note:**
- The Un-audited financial results for the quarter ended 30.09.2024 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.11.2024
 - This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
 - The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
 - The other expenses includes salary & other marketing expenses for domestic market and marketing expense for setting up network of Oncology Market
 - The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -Earning per Share
 - Limited Review has been carried out by the Statutory Auditors for the above period.
 - The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place :New Delhi
Date : 14.11.2024

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

41.79	4921.23	4706	4855.75
-	-	-	-
-	4250	-	4250
-	4.58	-	21.84
-	4.58	-	21.84

Results filed with the Stock Exchanges under Regulation 17(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Rules, 2015. The full format of the quarterly/half yearly (tradecorp.com) and website of Stock Exchange

Results for the quarter and half year ended 30.09.2024 have been approved by the Board of Directors in accordance with the Companies (Accounting Standards) Rules, 2015 (Ind AS) prescribed under the Companies Act, 2013 to the extent applicable.

By order of the Board of Directors
For Virtuous Tradecorp Private Limited
Bhartendu Harit
Director
DIN : 09000267

GAMA LIMITED

(Enterprise)
32044
Manjunathapur, Mysuru - 570 020.
Bengaluru, Anandarao Circle, Bengaluru- 560 009.

ended 30th, September 2024.

(₹. in lakh)	
Quarter ended	Previous year ended
30-09-2024	31-03-2024
Unaudited	Unaudited
Nil	Nil
12,204.60	29,916.19
12,204.60	29,916.19
7,030.95	13,652.33
9,929.20	24,903.72
14,498.80	29,469.11
15,569.35	30,769.47
47,028.30	98,794.63
(-34,823.70)	(-68,878.44)
NIL	NIL
NIL	Nil
(-34,823.70)	(-68,878.44)
NIL	NIL
NIL	NIL



MBL Infrastructure Ltd.

(CIN-L27109DL1995PLC338407)

Registered & Corporate Office: Baani Corporate One, Suite No. 308, 3rd Floor,
Plot No. 5, Commercial Centre, Jasola, New Delhi - 110025
Tel No. 011-48593300; Fax No. 011-48593320; www.mblinfra.com; email : cs@mblinfra.com

STATEMENT OF STANDALONE AND CONSOLIDATED UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

(₹. in Lakhs except earnings per share)